HHorinouchi· @HHorinouchi · X·· 2 天前评分60
正文 · 机器翻译
🆙#ESMO26 快速口头报告 I：#LCSM 转移性肿瘤 🔥COCOON：改善接受一线（1L）皮下（SC）Amivantamab + Lazertinib治疗的EGFR突变型晚期NSCLC患者中重度皮肤科不良事件的预防：新COCOON队列的首批结果 🎙️ @cbcbc1971 🔢2700RO 🎯通过补充锌优化皮肤科管理 🎯截至第12周，≥2级DAEIs占34% 🎯头皮5%，甲周炎18%；减量11%，停药3% ☑️NCT06120140 🔗 https://t.co/E2MIRGnkpb @OncoAlert @Larvol @myESMO @IASLC @EGFRResisters
热度 8 · 7 赞 · 0 回复 · 1 转发
会议摘要
NCT06120140NCT06120140按 - **标题 / Title：** Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib 对上
- **标题 / Title：** Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib读摘要原文 →来源：HHorinouchi · x.com